Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment

Related Experiment Video

Updated: Apr 1, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.3K

Xinbing Sui1,2, Yinghua Xu1, Xian Wang1,2

  • 1Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University , 310027 Hangzhou, China.

Molecular Pharmaceutics
|October 3, 2015
PubMed

Insights

Metformin, a common diabetes drug, shows potential anticancer effects by influencing cell metabolism and survival pathways. Further research is needed to clarify its mechanisms and clinical use in cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Metformin is a widely prescribed drug for type 2 diabetes mellitus.
  • Emerging evidence suggests metformin possesses anticancer properties.
  • Conflicting study results necessitate a comprehensive review of its antineoplastic activity.

Purpose of the Study:

  • To review the role of metformin in cancer prevention and treatment.
  • To summarize the molecular mechanisms underlying metformin's anticancer effects.
  • To discuss challenges in the clinical application of metformin for cancer.

Main Methods:

  • Literature review of retrospective data and laboratory studies.
  • Analysis of molecular pathways involved in metformin's action.
  • Discussion of existing scientific and clinical evidence.

Main Results:

  • Metformin's potential anticancer effects are linked to AMPK-dependent and independent pathways.
  • Aberrations in energy metabolism, cell cycle arrest, apoptosis, and autophagy are key mechanisms.
  • Evidence suggests metformin's role in various cancer types, though mechanisms require further elucidation.

Conclusions:

  • Metformin exhibits promising anticancer potential through multiple molecular pathways.
  • Further research is crucial to overcome scientific and clinical hurdles for its use in oncology.
  • Clarifying metformin's precise role in cancer treatment remains an active area of investigation.
Keywords:
AMPKcancermetforminpreventiontherapy

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
959
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.7K
Cancer Prevention02:59

Cancer Prevention

3.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
886
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K